Study of сanakinumab in patients with myelofibrosis

The company John Mascarenhas is commencing recruitment for the clinical trial of the Study of Canakinumab in Patients With Myelofibrosis.

The conditions are Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF.

The trial officially began on the July 2022 and is planned to complete on June 2024.

This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles. Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.

The link to the complete study profile:

Clinical Research News

Upcoming Clinical Trials